Cardioprotective effect of Rybelsus®: results of the SOUL study and upcoming FDA indication expansion
A Pill That Changed the Landscape Approved by the FDA in 2019, Rybelsus® (oral semaglutide) became the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes (T2D). This marked a paradigm shift for incretin-based therapies, which had previously required subcutaneous injections. Developed by Novo Nordisk, Rybelsus brought the clinically proven benefits of … Read more